Crescent Biopharma
Market cap $507M 38.9M shares (10-Q, Nov 11, 2026) × $13.04 close Nov 17, 2026
Most recent annual filing: 2026-02-26
- CR-001 + ADC combination trial2H 2026CR-001 + ADC combination trial, 2H 2026, notable
- CR-001 Ph1 topline1Q 2027CR-001 Ph1 topline, 1Q 2027, thesis-defining
- CR-003 / SKB105 Ph1 readout1Q 2027CR-003 / SKB105 Ph1 readout, 1Q 2027, material
- Portfolio corporate updatemid-2027Portfolio corporate update, mid-2027, routine
- CR-001 + Kelun-Biotech ADCs combination2H 2027CR-001 + Kelun-Biotech ADCs combination, 2H 2027, material
- CR-002 2 proof-of-concept Ph1 interim2H 2027CR-002 2 proof-of-concept Ph1 interim, 2H 2027, material
- CR-002 Ph1 start2H 2027CR-002 Ph1 start, 2H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
CR-003
SKB105- Undisclosed indication
CR-002
Capital (as filed)
- Cash
- $289M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$26.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $289M cash, runway second half of 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Offering documents (4)
- 2026-07-30 424B3 · Resale (selling stockholders)
- 2026-07-15 424B5 · Priced offering 8.09M shares · at $14.50 · $125M gross · 5.3% below the prior close ($15.31, Jul 14, 2026) · incl. pre-funded warrants
- 2026-07-01 S-3 · Shelf registration up to $200M aggregate
- 2026-06-22 424B3 · Resale (selling stockholders)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-13 UPDATE: Crescent Biopharma (CBIO) - The Tap Opened Into Strength 🔒 Paid
- 2026-10-16 UPDATE: Crescent Biopharma (CBIO) - The Big One Gets Smaller 🔒 Paid
- 2026-10-06 UPDATE: Crescent Biopharma (CBIO) - The Third Program Clears the Gate 🔒 Paid
- 2026-07-30 UPDATE: Crescent Biopharma (CBIO) - The Combination Trial Is Live 🔒 Paid
- 2026-07-20 UPDATE: Crescent Biopharma (CBIO) - The Architect Wrote a Check 🔒 Paid
- 2026-07-15 UPDATE: Crescent Biopharma (CBIO) - The Pricing Print Clears 🔒 Paid
- 2026-07-14 UPDATE: Crescent Biopharma (CBIO) - The Dilution Tap Opens 🔒 Paid
- 2026-07-01 UPDATE: Crescent Biopharma (CBIO) - The Shelf Goes Up Six Months Early 🔒 Paid
- 2026-05-11 Crescent Bio (CBIO) - Scientific Deep Dive for CR-001, CR-003, and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Crescent Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-11 Buy core Crescent Bio (CBIO) - Scientific Deep Dive for CR-001, CR-003, and Pipeline Products High-conviction play on a validated PD-1/VEGF bispecific architecture (CR-001) with a pristine balance sheet bridging to the Q1 2027 ASCEND catalyst, positioned as a premier M&A target for Big Pharma facing patent cliffs.
- 2026-07-01 Buy core UPDATE: Crescent Biopharma (CBIO) - The Shelf Goes Up Six Months Early Scientific thesis and Fairmount anchor intact, but the ATM filing introduces a dilution tap that caps upside asymmetry on the pre-catalyst run-up leg; accumulation thesis maintained with wider expected variance.
- 2026-07-14 Watch UPDATE: Crescent Biopharma (CBIO) - The Dilution Tap Opens Management launched an aggressive marketed follow-on at a 15% discount to the original accumulation zone six months before catalyst, breaking the pre-catalyst compounding trade; waiting for pricing print and sponsor-participation tea leaves before re-entering.
- 2026-07-15 Buy core UPDATE: Crescent Biopharma (CBIO) - The Pricing Print Clears The dilution overhang priced at $14.50 with the market absorbing the deal without imploding, creating a 30-day underwriter defense window and a known ATM re-arming date, making the post-pricing entry at $14.50–$15.70 a materially better setup for the same Q1 2027 catalyst on an over-funded balance sheet.
- 2026-07-20 Buy core UPDATE: Crescent Biopharma (CBIO) - The Architect Wrote a Check Fairmount's $20M participation in the follow-on via the pre-funded tranche is an ambiguously positive sponsor signal — not a full-throated green flag but better than silence — leaving the post-pricing BUY thesis intact.
- 2026-07-30 Buy core UPDATE: Crescent Biopharma (CBIO) - The Combination Trial Is Live Greenshoe fully exercised confirming healthy demand, pro forma cash of $305M into 2H 2028, and the CR-001 + sac-TMT Phase 2 now enrolling expand the thesis from a single Q1 2027 binary to four dated readouts across five quarters on an over-funded balance sheet.
- 2026-10-06 Buy core UPDATE: Crescent Biopharma (CBIO) - The Third Program Clears the Gate FDA IND clearance for CR-002 (APOLLO trial) lands on schedule, closing a key watch-list item and moving CR-002's 2H 2027 readout from planned to cleared, while the $305M balance sheet funds APOLLO without new dilution pressure.
- 2026-10-16 Buy core UPDATE: Crescent Biopharma (CBIO) - The Big One Gets Smaller Execution remains on track with dose escalation complete and 125+ patients dosed, but the Q1 2027 ASCEND efficacy readout is now confirmed as a 12-patient ORR snapshot — a noisier, smaller test than originally framed — making the mid-2027 combination data the more durable thesis test.
- 2026-11-13 Buy core UPDATE: Crescent Biopharma (CBIO) - The Tap Opened Into Strength Both open watch-list items resolved favorably — APOLLO dosed its first patient in Q4 as guided and the ATM was used opportunistically at ~$20/share (~40% above the July follow-on price) — confirming management is selling into strength rather than weakness ahead of the Q1 2027 ASCEND readout.
- Long call · opened May 11, 2026 at $18.52 · closed Jul 15, 2026 (downgraded to WATCH from long) at $15.67 · -15.4% vs XBI +15.9%
- Long call · opened Jul 16, 2026 at $15.11 · -13.7% vs XBI -4.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (7 quotes from 4 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Crescent is on track to report initial monotherapy data from ASCEND in the first quarter of 2027, including: ◦ Preliminary antitumor response as measured by overall response rate (ORR) from a first-line NSCLC cohort of up to 12 patients. 1 ◦ Safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 treatment-naïve and previously treated patients across multiple solid tumor types.”
matched to CR-001 · topline data -
“A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the first quarter of 2027.”
matched to CR-003 / SKB105 · readout other
-
-
-
“Initial data are expected in the second half of 2027.”
matched to CR-001 + Kelun-Biotech ADCs (combination) · readout other
-
-
-
“A Phase 1/2 combination trial of CR-003 and CR-001 is expected to initiate in the first half of 2027, with initial data anticipated by year-end 2027.”
matched to CR-001 · topline data -
“A Phase 1/2 trial of CR-003 (also known as SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the 2 first quarter of 2027.”
matched to CR-003 / SKB105 · readout other
-
-
-
“A Phase 1/2 combination trial of CR-003 and CR-001 is expected to initiate in the first half of 2027, with initial data anticipated by year-end 2027.”
matched to CR-001 · topline data -
“A Phase 1/2 trial of CR-003 (also known as SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the 2 first quarter of 2027.”
matched to CR-003 / SKB105 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (33)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseCrescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateCrescent's Q3 earnings confirm the first APOLLO patient dosed and reveal the ATM tapped for $11.1M in Q3 — two named watch-list items closed in a single quarter, with $289.4M cash still on hand and the Q1 2027 ASCEND binary closing fast.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseCrescent Biopharma to Present at November Investor Conferences
- Oct 15, 2026ReleaseCrescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis→ BD updateSummary on the 8-K
- Oct 15, 20268-KCurrent report: other events→ BD updateASCEND dose escalation is complete with 125+ patients dosed and the Q1 2027 monotherapy readout now has a defined scope: ORR from a 1L NSCLC cohort of up to 12 patients plus PK/PD/safety from the full dataset — and for the first time, management is explicitly guiding Phase 3 initiation in early 2028, signaling conviction that the data will support it.
- Oct 5, 2026ReleaseCrescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors→ BD updateThe FDA just cleared the CR-002 IND — the milestone I've flagged in every update since July as the key validation of the July financing's charitable read. The APOLLO Phase 1/2 trial launches this quarter, making Crescent a three-program clinical company heading into a stacked 2027 catalyst calendar.BD extracted 1 program update from this document → CBIO pipeline
- Sep 3, 2026ReleaseCrescent Biopharma to Present at September Investor Conferences
- Jul 30, 2026ReleaseCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → CBIO pipeline
- Jul 30, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → CBIO pipeline
- Jul 30, 2026424B3Prospectus (resale / update)
- Jul 30, 202610-QQuarterly report
- Jul 20, 2026SCHEDULE 13D/A13D amendment
- Jul 16, 2026ReleaseCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Jul 15, 20268-KCurrent report: other events · EX-99.1
- Jul 15, 2026424B5Prospectus supplement (offering)
- Jul 14, 2026ReleaseCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Jul 14, 2026ReleaseCrescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
- Jul 14, 20268-KCurrent report: results of operations
- Jul 14, 2026424B5Prospectus supplement (offering)
- Jul 1, 2026S-3Shelf registration
- Jun 22, 2026424B3Prospectus (resale / update)
- Jun 22, 202610-Q/AQuarterly report (amended)
- Jun 3, 20268-KCurrent report: shareholder vote
- Jun 2, 2026ReleaseCrescent Biopharma to Present at June Investor Conferences
- May 21, 2026ReleaseCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- Apr 29, 20268-KCurrent report: results of operations · EX-99.1
- Apr 29, 2026424B3Prospectus (resale / update)
- Apr 29, 202610-QQuarterly report
- Apr 21, 2026DEFA14AProxy soliciting material
- Apr 21, 2026DEFA14AProxy soliciting material
- Apr 21, 2026DEF 14AProxy statement
- Mar 17, 2026424B3Prospectus (resale / update)
14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Sep 18, 2026S-8Employee plan registration
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 31, 2026EFFECTRegistration effective
- Jul 30, 2026POS AMPost-effective amendment
- Jul 10, 2026EFFECTRegistration effective
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 3, 2026POS AMPost-effective amendment
- Mar 3, 2026EFFECTRegistration effective